InsidersTradesSigma
Follow the Processa Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Processa Pharmaceuticals, Inc. has logged 123 reports. Market capitalisation: €8.6m. The latest transaction was reported on 11 August 2026 (Levée d'options). Among the most active insiders: Lin Patrick. Every trade is free.
123
Insider Decl.
n/a
Thresholds
€651,849
45 ops.
Buy Volume
€367,982
4 ops.
Sell Volume
58Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 August 2026
Declarations123 total
1,600 sharesCommon StockSEC:0000897069-26-001602:0
203 sharesCommon StockSEC:0000897069-26-001466:0
1,986 shares@ US$2.690.090% mcap100.0% of flowCommon StockSEC:0000897069-26-001000:0
Canonical exit: 29 Jul 2026 (T+90)
1,511 shares@ US$2.690.068% mcap1.8% of flowCommon StockSEC:0000897069-26-001004:0
Canonical exit: 29 Jul 2026 (T+90)
2,034 shares@ US$2.690.092% mcap3.3% of flowCommon StockSEC:0000897069-26-001006:0
Canonical exit: 29 Jul 2026 (T+90)
2,190 shares@ US$2.690.099% mcap100.0% of flowCommon StockSEC:0000897069-26-001008:0
Canonical exit: 29 Jul 2026 (T+90)
1,706 shares@ US$2.690.077% mcap0.8% of flowCommon StockSEC:0000897069-26-001010:0
Canonical exit: 29 Jul 2026 (T+90)
2,136 shares@ US$2.5353.1% of flowCommon StockSEC:0000897069-26-000977:0
Canonical exit: 29 Jun 2026 (T+90)
1,843 shares@ US$2.970.091% mcap3.0% of flowCommon StockSEC:0000897069-26-000979:0
Canonical exit: 14 Jul 2026 (T+90)
1,799 shares@ US$2.970.089% mcap49.8% of flowCommon StockSEC:0000897069-26-000904:0
Canonical exit: 14 Jul 2026 (T+90)
1,369 shares@ US$2.970.068% mcap1.7% of flowCommon StockSEC:0000897069-26-000908:0
Canonical exit: 14 Jul 2026 (T+90)
1,843 shares@ US$2.970.091% mcap2.9% of flowCommon StockSEC:0000897069-26-000910:0
Canonical exit: 14 Jul 2026 (T+90)
1,984 shares@ US$2.970.098% mcap49.8% of flowCommon StockSEC:0000897069-26-000902:0
Canonical exit: 14 Jul 2026 (T+90)
1,545 shares@ US$2.970.076% mcap0.8% of flowCommon StockSEC:0000897069-26-000912:0
Canonical exit: 14 Jul 2026 (T+90)
789 shares@ US$2.535100.0% of flowCommon StockSEC:0000897069-26-000781:0
Canonical exit: 29 Jun 2026 (T+90)
2,269 shares@ US$2.53534.7% of flowCommon StockSEC:0000897069-26-000741:0
Canonical exit: 29 Jun 2026 (T+90)
2,107 shares@ US$2.53533.7% of flowCommon StockSEC:0000897069-26-000743:0
Canonical exit: 29 Jun 2026 (T+90)
1,603 shares@ US$2.5352.6% of flowCommon StockSEC:0000897069-26-000747:0
Canonical exit: 29 Jun 2026 (T+90)
2,136 shares@ US$2.5352.9% of flowCommon StockSEC:0000897069-26-000750:0
Canonical exit: 29 Jun 2026 (T+90)
2,072 shares@ US$2.53583.6% of flowCommon StockSEC:0000897069-26-000752:0
Canonical exit: 29 Jun 2026 (T+90)
2,324 shares@ US$2.53533.7% of flowCommon StockSEC:0000897069-26-000754:0
Canonical exit: 29 Jun 2026 (T+90)
1,810 shares@ US$2.5351.0% of flowCommon StockSEC:0000897069-26-000756:0
Canonical exit: 29 Jun 2026 (T+90)
25 of 123 declarations
关于 Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc.（股票代码：PCSA）是一家在美国纳斯达克市场交易的美国上市公司。公司总部位于马里兰州汉诺威，是一家小型临床阶段制药开发商，专注于未满足的医疗需求，特别关注肿瘤学和其他难治性疾病。Processa 成立于 2017 年，是在早期 Promet Therapeutics 相关结构重组后成立的，其战略围绕“监管科学”方法，旨在提高候选药物的疗效和耐受性。（[processapharmaceuticals.com](https://www.processapharmaceuticals.com/?utm_source=openai)） 其商业模式以推进开发阶段资产管线为中心，而非建立稳定的商业收入基础。Processa 在其自身材料中将自己描述为一家开发阶段的制药公司，致力于为治疗选择有限的患者创造下一代疗法。因此，其竞争地位更多地取决于科学执行、临床试验设计、监管信誉以及随着时间的推移获得融资的能力，而非当前的销售额。该公司强调其开发团队曾参与多项 FDA 批准和会议，这对于一家如此规模的生物技术公司而言是一项重要的能力。（[processapharmaceuticals.com](https://www.processapharmaceuticals.com/investors/company-information?utm_source=openai)） 从产品角度来看，Processa 专注于旨在提供比现有疗法更好的效益-风险比的候选药物，尤其是在肿瘤学领域。该公司将其项目描述为“下一代化疗”，并提及了与 FDA Project Optimus 计划相关的原则，这反映了对剂量优化和减少因不良反应导致的治疗中断的重视。这使得 Processa 处于临床开发中一个专业化、高风险、高回报的利基市场。（[processapharmaceuticals.com](https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/126/processa-pharmaceuticals-provides-product-pipeline-and?utm_source=openai)） 从地理上看，Processa 的业务主要位于美国，这对于一家没有广泛商业平台的临床阶段生物技术公司来说是典型的。其国际业务在此阶段仍然有限；因此，投资者关注的重点是管线进展、监管里程碑和资本获取，而非地域扩张。（[processapharmaceuticals.com](https://www.processapharmaceuticals.com/?utm_source=openai)） 近期里程碑包括股权融资活动，特别是 2025 年 1 月宣布的公开发行，以及 2026 年 3 月提交的 2025 财年年度报告修订文件。这些事件突显了其资产负债表仍然依赖资本市场，这是开发阶段生物制药公司的共同特征。因此，对于法国、比利时和瑞士的投资者而言，PCSA 应被视为一家投机性临床阶段公司，而非一家成熟的创收医疗保健公司。（[processapharmaceuticals.com](https://www.processapharmaceuticals.com/investors/sec-filings/all-sec-filings/content/0001493152-25-004298/0001493152-25-004298.pdf?utm_source=openai)）
